Maria Gabriela Belvisi

Title: Maria Gabriela Belvisi: Innovator in Gene Expression Inhibition

Introduction

Maria Gabriela Belvisi is a prominent inventor based in Aigburth, GB. She has made significant contributions to the field of gene expression inhibition, holding a total of 2 patents. Her work focuses on innovative methods to address diseases linked to the IKK-B gene.

Latest Patents

Belvisi's latest patents include compositions and methods for inhibiting the expression of the IKK-B gene. The invention involves a double-stranded ribonucleic acid (dsRNA) designed to inhibit the expression of the IKK-B gene. This dsRNA comprises an antisense strand with a nucleotide sequence that is less than 30 nucleotides in length, typically ranging from 19 to 25 nucleotides. This strand is substantially complementary to a portion of the IKK-B gene. Additionally, the invention encompasses a pharmaceutical composition that includes the dsRNA along with a pharmaceutically acceptable carrier. The methods outlined in her patents aim to treat diseases caused by the expression or activation of the IKK-B gene, as well as methods for inhibiting the gene's expression in cells.

Career Highlights

Throughout her career, Belvisi has worked with notable organizations, including Alnylam Pharmaceuticals, Inc. and Imperial College of Science, Technology and Medicine. Her expertise in the field has allowed her to contribute to groundbreaking research and development in gene therapy.

Collaborations

Some of her notable coworkers include Mark Andrew Birrell and Elizabeth Louise Hardaker. Their collaborative efforts have further advanced the research in gene expression and its implications for treating various diseases.

Conclusion

Maria Gabriela Belvisi stands out as an influential inventor in the realm of gene expression inhibition. Her innovative patents and collaborations reflect her commitment to advancing medical science and improving treatment options for patients.